Inflectra Approved as 'Biosimilar' to Remicade

WEDNESDAY, April 6, 2016 — The U.S. Food and Drug Administration has approved its second-ever “biosimilar” drug, Inflectra, for adults with Crohn’s disease, rheumatoid arthritis or chronic plaque psoriasis, among other prescribed uses.
In a media…
Source: Topamax